The role of thrombin in the pathogenesis of diabetic neuropathy.

Diabetic neuropathy is common and disabling despite glycemic control. Novel neuroprotective approaches are needed. Thrombin and hypercoagulability are associated with diabetes and nerve conduction dysfunction. Our aim was to study the role of thrombin in diabetic neuropathy. We measured thrombin act...

Full description

Bibliographic Details
Main Authors: Efrat Shavit-Stein, Ramona Aronovich, Constantin Sylantiev, Shany Guly Gofrit, Joab Chapman, Amir Dori
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0219453
id doaj-9ce70936db294acf80919875da1ef7e7
record_format Article
spelling doaj-9ce70936db294acf80919875da1ef7e72021-03-03T20:35:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01147e021945310.1371/journal.pone.0219453The role of thrombin in the pathogenesis of diabetic neuropathy.Efrat Shavit-SteinRamona AronovichConstantin SylantievShany Guly GofritJoab ChapmanAmir DoriDiabetic neuropathy is common and disabling despite glycemic control. Novel neuroprotective approaches are needed. Thrombin and hypercoagulability are associated with diabetes and nerve conduction dysfunction. Our aim was to study the role of thrombin in diabetic neuropathy. We measured thrombin activity by a biochemical assay in streptozotocin (STZ)-induced diabetic neuropathy in male Sprague-Dawley rats. Neuropathy severity was assessed by thermal latency and nerve conduction measures. Thermal latencies were longer in diabetic rats, and improved with the non-specific serine-protease inhibitor Tosyl-L-lysine-chloromethyl ketone (TLCK) treatment (p<0.01). The tail nerve of diabetic rats showed slow conduction velocity (p˂0.01), and interestingly, increased thrombin activity was noted in the sciatic nerve (p˂0.001). Sciatic nodes of Ranvier and the thrombin receptor, protease activated receptor 1 (PAR1) reactivity showed abnormal morphology in diabetic animals by immunofluorescence staining (p<0.0001). Treatment of diabetic animals with either the specific thrombin inhibitor, N-alpha 2 naphtalenesulfonylglycyl alpha-4 amidino-phenylalaninepiperidide (NAPAP) or TLCK preserved normal conduction velocity, (p˂0.01 and p = 0.01 respectively), and prevented disruption of morphology (p˂0.05 and p˂0.03). The results establish for the first time an association between diabetic neuropathy and excessive activation of the thrombin pathway. Treatment of diabetic animals with thrombin inhibitors ameliorates both biochemical, structural and electrophysiological deficits. The thrombin pathway inhibition may be a novel neuroprotective therapeutic target in the diabetic neuropathy pathology.https://doi.org/10.1371/journal.pone.0219453
collection DOAJ
language English
format Article
sources DOAJ
author Efrat Shavit-Stein
Ramona Aronovich
Constantin Sylantiev
Shany Guly Gofrit
Joab Chapman
Amir Dori
spellingShingle Efrat Shavit-Stein
Ramona Aronovich
Constantin Sylantiev
Shany Guly Gofrit
Joab Chapman
Amir Dori
The role of thrombin in the pathogenesis of diabetic neuropathy.
PLoS ONE
author_facet Efrat Shavit-Stein
Ramona Aronovich
Constantin Sylantiev
Shany Guly Gofrit
Joab Chapman
Amir Dori
author_sort Efrat Shavit-Stein
title The role of thrombin in the pathogenesis of diabetic neuropathy.
title_short The role of thrombin in the pathogenesis of diabetic neuropathy.
title_full The role of thrombin in the pathogenesis of diabetic neuropathy.
title_fullStr The role of thrombin in the pathogenesis of diabetic neuropathy.
title_full_unstemmed The role of thrombin in the pathogenesis of diabetic neuropathy.
title_sort role of thrombin in the pathogenesis of diabetic neuropathy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description Diabetic neuropathy is common and disabling despite glycemic control. Novel neuroprotective approaches are needed. Thrombin and hypercoagulability are associated with diabetes and nerve conduction dysfunction. Our aim was to study the role of thrombin in diabetic neuropathy. We measured thrombin activity by a biochemical assay in streptozotocin (STZ)-induced diabetic neuropathy in male Sprague-Dawley rats. Neuropathy severity was assessed by thermal latency and nerve conduction measures. Thermal latencies were longer in diabetic rats, and improved with the non-specific serine-protease inhibitor Tosyl-L-lysine-chloromethyl ketone (TLCK) treatment (p<0.01). The tail nerve of diabetic rats showed slow conduction velocity (p˂0.01), and interestingly, increased thrombin activity was noted in the sciatic nerve (p˂0.001). Sciatic nodes of Ranvier and the thrombin receptor, protease activated receptor 1 (PAR1) reactivity showed abnormal morphology in diabetic animals by immunofluorescence staining (p<0.0001). Treatment of diabetic animals with either the specific thrombin inhibitor, N-alpha 2 naphtalenesulfonylglycyl alpha-4 amidino-phenylalaninepiperidide (NAPAP) or TLCK preserved normal conduction velocity, (p˂0.01 and p = 0.01 respectively), and prevented disruption of morphology (p˂0.05 and p˂0.03). The results establish for the first time an association between diabetic neuropathy and excessive activation of the thrombin pathway. Treatment of diabetic animals with thrombin inhibitors ameliorates both biochemical, structural and electrophysiological deficits. The thrombin pathway inhibition may be a novel neuroprotective therapeutic target in the diabetic neuropathy pathology.
url https://doi.org/10.1371/journal.pone.0219453
work_keys_str_mv AT efratshavitstein theroleofthrombininthepathogenesisofdiabeticneuropathy
AT ramonaaronovich theroleofthrombininthepathogenesisofdiabeticneuropathy
AT constantinsylantiev theroleofthrombininthepathogenesisofdiabeticneuropathy
AT shanygulygofrit theroleofthrombininthepathogenesisofdiabeticneuropathy
AT joabchapman theroleofthrombininthepathogenesisofdiabeticneuropathy
AT amirdori theroleofthrombininthepathogenesisofdiabeticneuropathy
AT efratshavitstein roleofthrombininthepathogenesisofdiabeticneuropathy
AT ramonaaronovich roleofthrombininthepathogenesisofdiabeticneuropathy
AT constantinsylantiev roleofthrombininthepathogenesisofdiabeticneuropathy
AT shanygulygofrit roleofthrombininthepathogenesisofdiabeticneuropathy
AT joabchapman roleofthrombininthepathogenesisofdiabeticneuropathy
AT amirdori roleofthrombininthepathogenesisofdiabeticneuropathy
_version_ 1714821676215042048